mafosfamide

1.	Blaney, Susan M: 2 articles (04/2008 - 01/2005)
2.	Scorsone, Kathy: 1 article (04/2008)
3.	Berg, Stacey L: 1 article (04/2008)
4.	D'Argenio, David Z: 1 article (04/2008)
5.	Jacob, Eufemia: 1 article (04/2008)
6.	Kilianska, Zofia M: 1 article (12/2006)
7.	Hanausek, Malgorzata: 1 article (12/2006)
8.	Robak, Tadeusz: 1 article (12/2006)
9.	Blonski, Jerzy Z: 1 article (12/2006)
10.	Bednarek, Jolanta: 1 article (12/2006)

Related Diseases

1.	Leukemia 11/01/1989 - "Pharmacological purging with the oxazaphosphorine derivative mafosfamide has been studied extensively, and recent clinical data suggest that purging with mafosfamide may translate into superior remission duration if compared to nonpurged ABMT in acute leukemia" 01/01/1989 - "Drug-mediated marrow purging: mafosfamide in adult acute leukemia in remission" 12/01/1999 - "In this study of autotransplantation for acute leukemia using mafosfamide-purged marrow, the stem cell dose used for purging and the intensity of purging were the most important factors predicting outcome." 04/09/1990 - "Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies." 12/01/1999 - "We retrospectively analyzed patients with acute leukemia autografted with marrow purged with mafosfamide after January 1983 in our institution" Order ALL the reference details at left...
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1993 - "Techniques for pharmacological marrow decontamination, clinical result obtained with ABMT and the efficacy of ABMT with mafosfamide purged marrow in patients with acute myelogenous leukemia are reviewed." 12/01/2001 - "Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging." 01/01/1990 - "The analysis of clinical data in terms of disease-free survival (DFS) shows that the "programmed method" gives significantly better results than those obtained using the standard dose of mafosfamide (80% DFS in 18 AL patients vs. 44% in 33 ANLL patients and 33% in 56 ALL patients)" 01/01/1991 - "Autologous marrow transplantation in first remission acute myeloid leukemia using marrow purged with mafosfamide." 04/01/1996 - "All seven had acute myeloblastic leukemia (AML) and underwent an autologous marrow transplantation (ABMT) with a marrow purged in vitro by mafosfamide" Order ALL the reference details at left...
3.	Neoplasms (Cancer) 07/01/1993 - "Our results indicate that a combination of a conventional chemotherapeutic agent and a tumor-specific antisense oligodeoxynucleotide is highly effective in killing leukemic cells and in sparing a much higher number of normal progenitor cells as compared with high-dose mafosfamide treatment" 10/01/1996 - "These were cis-platin and mafosfamide, which are widely used for the management of solid tumors" 01/01/1989 - "The influence of cis-4-sulfoethylthio-cyclophosphamide (mafosfamide) on natural killer cell activity was examined in vitro in order further to elucidate the possible immunological mechanisms of tumor regressions following low-dose oxazaphosphorine therapy" 01/01/1989 - "In nude mice treatment of the L5222 with low doses of mafosfamide also resulted in surviving animals, however resistance to a second tumor challenge occurred only sporadically" 11/01/1988 - "Secondly, bone marrow cells were incubated with cancer drugs such as 4-HC or mafosfamide" Order ALL the reference details at left...
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/1992 - "Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow." 03/01/1992 - "It, therefore, was the aim of the present study to investigate in a group of patients with acute nonlymphoblastic leukemia (ANLL; n = 19) and acute lymphoblastic leukemia (ALL; n = 19) in complete remission the effect of mafosfamide at the level of adherent blast colony-forming units (blast colony-forming units, CFU-Blast), as well as multipotential (granulocyte erythrocyte macrophage megakaryocyte colony-forming units, CFU-GEMM), erythroid (erythroid burst-forming units, BFU-E), and granulocyte-macrophage (granulocyte-macrophage colony-forming units, CFU-GM) progenitor cells" 01/01/2002 - "In the group of initial Acute Lymphoblastic Leukemia (ALL) samples, equivalent cytotoxicity values for glufosfamide, 4-HOO-ifosfamide, 4-HOO-cyclophosphamide and mafosfamide were 5.95, 9.92, 4.60 and 3.90 microg/ml, respectively" 05/01/1994 - "Primary cyclophosphamide-naive clonogenic blasts from 32 patients with newly diagnosed acute lymphoblastic leukemia (ALL) were tested for their in vitro sensitivity to an "activated" cyclophosphamide, viz., mafosfamide, using leukemic progenitor cell (LPC) colony assays" 05/01/1994 - "Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide." Order ALL the reference details at left...
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/1993 - "Successful mafosfamide purging of bone marrow from chronic myelogenous leukemia (CML) cells." 01/01/1990 - "We studied the SCE-inducing effect of mafosfamide on leukemic cells of Philadelphia (Ph)-positive chronic myeloid leukemia (CML) as a model for leukemic cells" 01/01/1990 - "Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias" 09/01/1994 - "Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous transplantation using marrow treated ex vivo with mafosfamide" 09/01/1994 - "Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	Morphine (MS Contin)
3.	Dexamethasone (Maxidex)
4.	perfosfamide
5.	Asta Z 7557
6.	Etoposide (VP 16)
7.	Ifosfamide
8.	glucosyl-ifosfamide mustard (glufosfamide)
9.	aldophosphamide
10.	Nigericin

Related Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
2.	Autologous Transplantation (Autograft)
3.	Transplantation (Transplant Recipients)
4.	Drug Therapy (Chemotherapy)
5.	Premedication

Best Treatments:
Research Summary Report
on Leukemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1761 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>